INTRODUCTION AND OBJECTIVES: Human papillomavirus (HPV) is commonly present in semen sample. However, whether the presence of HPV in semen is actually associated with impaired semen parameters and sperm DNA fragmentation (SDF) values has yet to be elucidated. We aimed to assess the impact of the presence of HPV in semen over the seminal parameters and SDF values in primary infertile men.
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METHODS: Complete data from 729 infertile men were analysed. Comorbidities were scored with the Charlson Comorbidity index (CCI). Serum hormones and sperm DNA fragmentation index (SDF; SDF !30% was defined as pathologic) were measured in every patient. Semen analysis was based on 2010 WHO reference criteria. Amplification by nested polymerase chain reaction (PCR) was used to detect HPV-DNA sequences in semen samples. Descriptive statistics and linear regression models tested the association between HPV presence and clinical and seminal characteristics in the whole cohort.
RESULTS METHODS: We retrospectively reviewed IUI outcomes from January 2012 to March 2015 from a large IVF center. Patients who were found to a have a confirmed clinical pregnancy (ultrasound confirmed heartbeat) were contacted to determine live birth rate and the presence of birth abnormalities. The Shapiro-Wilk test was used to determine if variables were normally distributed. Measures of central tendencies and variability were reported as mean and standard deviation, respectively. Chi-square analysis was used to assess difference between 4% or greater and <4% sperm morphology. Chi-square test was used to assess p-value for the trend between Total Motile Count (TMC) and percent pregnancy, spontaneous abortion, and live births.
RESULTS: During our study period, a total of 1470 IUI cycles were performed with a per cycle clinical pregnancy rate of 10.7% (n[158). Of those 158 patients, we were able to contact 93 patients (59% response rate) who reported 70 live births and 23 miscarriages. Only 4 birth abnormalities were reported. Median TMC between morphology <4%, 4% or greater was 11.8 million and 11.5 million, respectively, p [ 0.10. We found no difference in the rate of ultrasound confirmed clinical pregnancy (p [ 0.82), spontaneous abortion (p [ 0.25) or live birth (p [ 0.35) among couples with a sperm morphology <4% as compared to 4% or greater. When stratified by TMC of <5 million, 5-9 million, and >9 million, there was also no difference in the rate of the clinical pregnancy, live birth rate or birth abnormalities.
CONCLUSIONS: Our data is the first to report no difference in live birth rate and no increased risk of birth abnormalities for those with sperm morphology less than 4% undergoing IUI. Isolated abnormal sperm morphology should not be an indication for the need for IVF because there appears to be no difference in live birth outcomes or congenital abnormalities as compared to men with sperm morphology 4% or greater.
